First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis

BACKGROUND: This study evaluated the cost-effectiveness of nivolumab plus chemotherapy (NC) or ipilimumab versus chemotherapy as a first-line treatment for advanced esophageal squamous cell carcinoma (ESCC) in the United States and China. METHODS: A partitioned survival model was constructed from th...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Xueqiong, Cai, Hongfu, Li, Na, Zheng, Bin, Zheng, Zhiwei, Liu, Maobai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486256/
https://www.ncbi.nlm.nih.gov/pubmed/36147862
http://dx.doi.org/10.1177/17588359221122733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486256/
https://www.ncbi.nlm.nih.gov/pubmed/36147862
http://dx.doi.org/10.1177/17588359221122733

Ejemplares similares